UBS analyst David Lai upgraded Nuvalent (NUVL) to Buy from Neutral with an unchanged price target of $100. The shares have been “beaten down” since September 2024, driven largely by the tough biotech tape and macro environment, the analyst tells investors in a research note. However, the firm believes the stock remains solid fundamentally with two “potentially best-in-class therapies” for non-small cell lung cancer with a combined $3.3B peak sales opportunity. UBS sees several near-term catalysts over the next 12 months for Nuvalent and a favorable risk/reward for the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent’s Promising Oncology Position and Strategic Differentiation Justify Buy Rating
- Nuvalent’s Strategic Expansion and Clinical Progress Drive Buy Rating
- Nuvalent’s Promising Clinical Trials and Financial Stability Earn Buy Rating from Analyst
- Nuvalent’s Strategic Advances in NSCLC Trials Justify Buy Rating
- Nuvalent, Inc. Reports 2024 Financial Results and Pipeline Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue